Zacks Research Issues Negative Forecast for PBH Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Research analysts at Zacks Research cut their Q1 2027 earnings estimates for shares of Prestige Consumer Healthcare in a note issued to investors on Monday, June 16th. Zacks Research analyst R. Department now expects that the company will earn $1.25 per share for the quarter, down from their prior estimate of $1.26. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q3 2027 earnings at $1.29 EPS.

Other analysts have also issued reports about the company. Royal Bank Of Canada upgraded Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Wall Street Zen upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 17th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, Prestige Consumer Healthcare presently has a consensus rating of "Moderate Buy" and a consensus target price of $93.33.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock traded down $0.27 on Thursday, reaching $83.37. 362,361 shares of the company traded hands, compared to its average volume of 298,971. The company has a 50 day moving average of $83.93 and a 200 day moving average of $82.51. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.20 and a quick ratio of 2.82. Prestige Consumer Healthcare has a 52 week low of $64.94 and a 52 week high of $90.04. The firm has a market capitalization of $4.12 billion, a PE ratio of 19.43, a PEG ratio of 2.50 and a beta of 0.45.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping analysts' consensus estimates of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The company had revenue of $296.52 million for the quarter, compared to analysts' expectations of $289.36 million. During the same period in the previous year, the business posted $1.02 EPS. The business's revenue for the quarter was up 7.0% compared to the same quarter last year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently modified their holdings of PBH. Cerity Partners LLC boosted its stake in Prestige Consumer Healthcare by 3.7% during the 1st quarter. Cerity Partners LLC now owns 3,666 shares of the company's stock valued at $315,000 after purchasing an additional 132 shares during the last quarter. Franklin Resources Inc. increased its holdings in Prestige Consumer Healthcare by 0.7% in the 4th quarter. Franklin Resources Inc. now owns 21,735 shares of the company's stock worth $1,697,000 after buying an additional 150 shares in the last quarter. KBC Group NV increased its holdings in Prestige Consumer Healthcare by 7.4% in the 1st quarter. KBC Group NV now owns 2,199 shares of the company's stock worth $189,000 after buying an additional 151 shares in the last quarter. CIBC Private Wealth Group LLC raised its position in Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after buying an additional 152 shares during the last quarter. Finally, McIlrath & Eck LLC lifted its stake in Prestige Consumer Healthcare by 19.1% during the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock valued at $75,000 after acquiring an additional 154 shares during the period. 99.95% of the stock is currently owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.